GPR39 Zn(2+)-sensing receptor: a new target in antidepressant development?

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Zinc is a trace element modulating neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors.
• Zinc exhibits antidepressant-like properties, supported by preclinical and clinical evidence.
• The GPR39 receptor senses zinc and is implicated in neuroprotection and depression.

Purpose of the Study:

• To explore the role of zinc and the GPR39 receptor in depression.
• To investigate the signaling pathways activated by zinc binding to GPR39.
• To evaluate GPR39 as a potential therapeutic target for depression.

Main Methods:

• Review of preclinical and clinical studies on zinc and depression.
• Analysis of the molecular mechanisms involving GPR39 activation by zinc.
• Examination of the relationship between zinc deficiency, GPR39 expression, and depressive behaviors.

Main Results:

• Zinc deficiency is associated with depressive-like behavior and reduced GPR39 expression.
• Zinc binding to GPR39 initiates CRE-dependent gene transcription, increasing neuroprotective proteins like BDNF.
• Antidepressant treatments often up-regulate GPR39, suggesting its involvement in antidepressant action.

Conclusions:

• The GPR39 receptor is a key mediator of zinc's antidepressant effects.
• Targeting the GPR39 receptor represents a promising strategy for novel depression therapeutics.
• Restoring zinc homeostasis may be beneficial for individuals with depression.